- Home
- PROK vs VNDA Comparison
PROK vs VNDA Comparison
Compare PROK & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | VNDA |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.0M | 301.1M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PROK | VNDA |
|---|---|---|
| Price | $1.71 | $4.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $6.25 | ★ $11.75 |
| AVG Volume (30 Days) | ★ 1.2M | 598.5K |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $893,000.00 | ★ $216,105,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | $7.83 | $35.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1075.00 | 8.72 |
| 52 Week Low | $1.30 | $4.27 |
| 52 Week High | $3.48 | $9.91 |
Technical Indicators
Market Signals| Indicator | PROK | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 39.46 |
| Support Level | $1.56 | $4.45 |
| Resistance Level | $1.97 | $5.37 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 22.73 | 8.16 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.